Abraham Lincoff, MD
Cardiovascular Disease · Cleveland, OHNPI 1427141902
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $283,719 of the $369,057 with a category attached, or 76.9%. 17 manufacturers reported payments, led by Novo Nordisk AS at 44.2% of the total. Among cardiovascular disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $2335.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$163K
- Novo Nordisk$66K
- Eli Lilly$45K
- Ardelyx, Inc.$11K
- Novartis$11K
- Medtronic$11K
- plus $63K from 11 others
Across 80 payments — averaging $41,340 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$3.1M
- Novo Nordisk AS$113K
- CSL Behring$56K
- AbbVie$903
What the payments were for
- Consulting fees$283,71977%
- Speaking & faculty fees$12,1353%
- Travel & lodging$68,81919%
- Food & beverage$4,3841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 56 | $163,236 |
| Novo Nordisk | 32 | $65,611 |
| Eli Lilly | 49 | $44,745 |
| Ardelyx, Inc. | 1 | $11,200 |
| Novartis | 1 | $11,088 |
| Medtronic(2 entities) | 6 | $10,652 |
| Alnylam Pharmaceuticals Inc. | 1 | $10,575 |
| Akebia Therapeutics Inc | 1 | $9,800 |
| Endologix LLC | 1 | $9,800 |
| BD | 1 | $9,800 |
| GSK | 1 | $8,400 |
| Neovasc Medical Inc | 1 | $7,425 |
| Bayer Healthcare LLC | 2 | $3,505 |
| Amgen | 1 | $2,639 |
| CSL Behring | 1 | $385 |
| Astrazeneca UK Limited | 2 | $110 |
| Esperion Therapeutics, Inc. | 1 | $87 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$369,057 in reported general payments places this provider in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 123 | $104,671 |
| EliquisApixaban | 48 | $57,260 |
| BrilintaTicagrelor | 22 | $16,252 |
| Praluent PenAlirocumab | 23 | $13,634 |
| Ranolazine ErRanolazine | 38 | $6,588 |
| Ezetimibe | 201 | $5,660 |
| Atorvastatin Calcium | 343 | $4,278 |
| Rosuvastatin Calcium | 185 | $3,704 |
| Metoprolol Succinate | 170 | $2,950 |
| ClopidogrelClopidogrel Bisulfate | 175 | $2,140 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 76 | $2,000 |
| Losartan Potassium | 110 | $1,001 |
| Amlodipine Besylate | 202 | $959 |
| Lisinopril | 144 | $944 |
| Valsartan | 32 | $529 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Cleveland
- Guilherme AttizzaniCleveland$1.3M
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Mazen HannaCleveland$208K
- Brian HoitCleveland$207K
- Steven NissenCleveland$149K
- Daniel CantillonCleveland$140K
- Serge HarbCleveland$134K
- Wael JaberCleveland$124K
- Milind DesaiCleveland$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.